此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

差异目标多重脊髓刺激 (DETECT)

2026年11月16日 更新者:Moens Maarten

差异目标多重脊髓刺激:一项多中心队列研究

Evaluation of the effectiveness of differential target multiplexed spinal cord stimulation for treatment of chronic back and leg pain. Additionally, a subgroup analysis will be performed to evaluate potential differences between paddle/surgical leads versus percutaneous leads.

研究概览

研究类型

观察性的

注册 (估计的)

250

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Antwerp、比利时
        • ZNA
      • Bruges、比利时
        • AZ Sint-Jan Brugge-Oostende
      • Bruges、比利时
        • AZ Sint-Lucas Brugge
      • Hasselt、比利时
        • Jessa Ziekenhuis
      • Kortrijk、比利时
        • AZ Groeninge
      • Leuven、比利时
        • UZ Leuven
      • Lier、比利时
        • Heilig Hart Ziekenhuis Lier
      • Liège、比利时
        • Centre Hospitalier Régional (CHR) de la Citadelle
      • Mechelen、比利时
        • AZ Sint-Maarten
      • Roeselare、比利时
        • AZ Delta
      • Sint-Niklaas、比利时
        • Vitaz
      • Turnhout、比利时
        • AZ Turnhout
      • Wilrijk、比利时
        • GZA
    • Brussels Capital
      • Jette、Brussels Capital、比利时、1090
        • Universitair Ziekenhuis Brussel

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Patients with chronic back and leg pain due to Failed Back Surgery Syndrome (FBSS)/Persistent Spinal Pain Syndrome type 2 (PSPS-T2), who will receive treatment with differential target multiplexed (DTM) SCS.

描述

Inclusion Criteria:

  • Patients with severe chronic pain (> 5 on numeric rating scale, NRS) for at least 6 months due to FBSS (PSPS T2) and suitable for treatment with DTM SCS according to the treating physician
  • Age > 18 years
  • Patient has been informed of the study procedures and has given written informed consent
  • Patient willing to comply with study protocol including attending the study visits

Exclusion Criteria:

  • Expected inability of the patient to receive or properly operate the spinal cord stimulation system
  • History of coagulation disorder, lupus erythematosus, diabetic neuropathy, rheumatoid arthritis, or morbus Bechterew
  • Active malignancy
  • Addiction to drugs, alcohol (>5 units per day) and/or medication
  • Evidence of an active disruptive psychiatric disorder or other known condition that may impact perception of pain, compliance to the intervention, and/or ability to evaluate treatment outcome as determined by investigator
  • Immune deficiency (e.g. HIV positive, immunosuppressive treatment)
  • Life expectancy < 1 year
  • Local infection or any other skin disorder at site of incision
  • Pregnancy
  • Other implanted active medical device

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
干预/治疗
Spinal cord stimulation

Patients will receive differential target multiplexed spinal cord stimulation

differential target multiplexed stimulation

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Overall pain intensity with Visual Analogue Scale (VAS)
大体时间:The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months

Overall pain, defined as a combination of back and leg pain, but not pain from other body parts, measured with the VAS (100mm)

The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months

次要结果测量

结果测量
措施说明
大体时间
使用视觉模拟量表 (VAS) 的背痛强度
大体时间:DTM刺激后1个月、6个月和12个月基线筛选与评估的变化
DTM刺激后1个月、6个月和12个月基线筛选与评估的变化
视觉模拟量表 (VAS) 的腿痛强度
大体时间:DTM刺激后1个月、6个月和12个月基线筛选与评估的变化
DTM刺激后1个月、6个月和12个月基线筛选与评估的变化
临床整体反应状态
大体时间:DTM刺激后1个月、6个月和12个月基线筛选与评估的变化
DTM刺激后1个月、6个月和12个月基线筛选与评估的变化
成功的 DTM 试验的比例。
大体时间:在最终 SCS 植入后进行评估
在最终 SCS 植入后进行评估
电池消耗
大体时间:DTM SCS 1个月、6个月和12个月注册
DTM SCS 1个月、6个月和12个月注册
关于 DTM SCS 编程的技术问题的普遍性
大体时间:在整个学习期间
在整个学习期间
DTM SCS 刺激参数
大体时间:DTM SCS 1个月、6个月和12个月注册
DTM SCS 1个月、6个月和12个月注册
Pain medication use
大体时间:The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months

Open question regarding the dosage, frequency and type of pain medication

The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
Functional disability
大体时间:The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months

The functional disabilities will be assessed with the Oswestry Disability Index (ODI)

The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
Health related quality of life
大体时间:The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months

Health related quality of life, evaluated with the EuroQol with five dimensions and 5 levels

The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
Patient global impression of change
大体时间:Evaluated at 1 month, 6 months and 12 months of DTM SCS.

Patients will be asked to quantify the impression of change after treatment using the Patient Global Impression of Change scale (PGIC).

Evaluated at 1 month, 6 months and 12 months of DTM SCS.
Patients' individual competencies for self-management
大体时间:The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months

Patient activation measure-13 (PAM) is a 13-item instrument which assesses self-reported behaviour, knowledge, and confidence for self-management of one's health.

The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
Work status
大体时间:The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months

Work status is evaluated with a self-designed questionnaire

The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
Pain catastrophizing
大体时间:The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months

The Pain Catastrophizing Scale (PCS) will be used to measure the level of pain catastrophizing

The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
Symptoms of central sensitisation.
大体时间:The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months

The Central Sensitization Inventory is used to measure symptoms of central sensitisation

The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
Anxiety and Depression.
大体时间:The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months

The hospital Anxiety and Depression Scale (HADS) will measure symptoms of anxiety and depression

The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
Healthcare utilisation.
大体时间:The change between implantation and evaluation at 1 month, 6 months and 12 months of DTM SCS

Postoperative healthcare expenditure will be investigated by self-reporting methods.

The change between implantation and evaluation at 1 month, 6 months and 12 months of DTM SCS
Time spent in body postures
大体时间:The data will be extracted from SCS implantation up to 1 month of SCS, from 1 month of SCS up to 6 months and from 6 months up to 12 months

Based on the AdaptiveStim technology, the time spent in body postures can be recorded.

The data will be extracted from SCS implantation up to 1 month of SCS, from 1 month of SCS up to 6 months and from 6 months up to 12 months
(Serious) adverse events
大体时间:Throughout study period

Systematically recording all adverse events

Throughout study period
Patient expectations concerning SCS
大体时间:Evaluated at baseline visit

Self-constructed open question to evaluate patient expectations about SCS

Evaluated at baseline visit

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2021年10月6日

初级完成 (估计的)

2027年1月1日

研究完成 (估计的)

2027年1月1日

研究注册日期

首次提交

2021年9月9日

首先提交符合 QC 标准的

2021年9月26日

首次发布 (实际的)

2021年10月5日

研究记录更新

最后更新发布 (实际的)

2026年11月17日

上次提交的符合 QC 标准的更新

2026年11月16日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅